Kyverna Therapeutics, Inc.KYTX
Price (close)
$6.99
Market cap
$432.3M
P/E
—
Revenue (TTM)
—
Net income
-$152.6M
Dividend yield
—
1-year total return
10.1%
Net margin
—
Revenue growth
—
Debt / equity
0.15x
What Kyverna Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net income | — | -$60.4M | -$127.5M | -$161.3M |
| Free cash flow | — | -$53.0M | -$116.5M | -$153.7M |
More on KYTX.
- Kyverna Therapeutics, Inc. summary
- Kyverna Therapeutics, Inc. financial statements
- Kyverna Therapeutics, Inc. key metrics
- Kyverna Therapeutics, Inc. health scores and style box
- Kyverna Therapeutics, Inc. earnings
- Kyverna Therapeutics, Inc. dividends
- Kyverna Therapeutics, Inc. valuation
- Kyverna Therapeutics, Inc. ownership and insiders
- Kyverna Therapeutics, Inc. peers
Figures from Kyverna Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.